<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Diseases affecting host defense mechanisms include <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:hpo ids='HP_0001888'>lymphocytopenia</z:hpo> (B- and <z:mp ids='MP_0008037'>T-lymphocyte abnormalities</z:mp>), deficiencies of complement, splenectomy, <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, <z:hpo ids='HP_0000083'>renal failure</z:hpo>, and <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Immunocompromised patients face frequent life-threatening complications of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, particularly when they are hospitalized and receiving cytotoxic myelosuppressive drugs </plain></SENT>
<SENT sid="2" pm="."><plain>Oral antimicrobial agents affect the flora of the host's alimentary tract, enhancing colonization by resistant, potentially pathogenic, strains and species, especially in a hospital environment </plain></SENT>
<SENT sid="3" pm="."><plain>Nalidixic acid, oxolinic acid, pipemidic acid, polymyxins, co-trimoxazole, <z:chebi fb="0" ids="26177">polyene antibiotics</z:chebi>, and <z:chebi fb="0" ids="7508">framycetin</z:chebi>, which preserve anaerobic colon flora, do not affect the host's colonization resistance and can be given in oral doses high enough to suppress and clear susceptible potential pathogens from the intestinal tract </plain></SENT>
<SENT sid="4" pm="."><plain>Such prophylactic treatment permits patients to stay hospitalized in ward conditions </plain></SENT>
<SENT sid="5" pm="."><plain>In the compromised host who has <z:hpo ids='HP_0001945'>fever</z:hpo> and suspected <z:mpath ids='MPATH_681'>septicemia</z:mpath>, a decision concerning treatment should be made within an hour of notification of the patient's condition </plain></SENT>
<SENT sid="6" pm="."><plain>In <z:hpo ids='HP_0011009'>acute</z:hpo> stages of life-threatening <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, the principal aim of antimicrobial chemotherapy is to provide the most potent treatment; at this stage, the accompanying side effects are less important </plain></SENT>
<SENT sid="7" pm="."><plain>An essential component of therapy should be an <z:chebi fb="0" ids="47779">aminoglycoside</z:chebi> paired with a <z:chebi fb="0" ids="35627">beta-lactam</z:chebi> antibiotic </plain></SENT>
<SENT sid="8" pm="."><plain>Because the incidence of staphylococcal resistance to antibiotics is high, preliminary sensitivity-testing is essential when staphylococcal <z:hpo ids='HP_0100806'>sepsis</z:hpo> threatens the life of a compromised host </plain></SENT>
<SENT sid="9" pm="."><plain>Despite aggressive antibiotic therapy, more than half of immunocompromised patients and patients with severe underlying diseases die when <z:mp ids='MP_0001795'>gram-negative</z:mp> bacteria invade their blood </plain></SENT>
<SENT sid="10" pm="."><plain>In these patients, medical or surgical removal of the septic focus is a major part of management, but plasma or plasma fractions should be given to correct <z:hpo ids='HP_0011106'>hypovolemia</z:hpo>, and an agent such as <z:chebi fb="40" ids="18243">dopamine</z:chebi> should be administered if volume replacement fails to restore adequate blood pressure </plain></SENT>
<SENT sid="11" pm="."><plain>A high dose of <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> should have a beneficial effect, and, for neutropenic patients with <z:mp ids='MP_0001795'>gram-negative</z:mp> <z:e sem="disease" ids="C0004610" disease_type="Disease or Syndrome" abbrv="">bacteremia</z:e> or <z:hpo ids='HP_0001945'>fever</z:hpo>, transfusion with functional neutrophils improves survival </plain></SENT>
</text></document>